SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation into Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Aegerion, Inc.

NEW YORK--(BUSINESS WIRE)--

Levi & Korsinsky announces it has commenced an investigation of Aegerion, Inc. ("Aegerion" or the "Company") AEGR concerning possible breaches of fiduciary duty.

On May 12, 2016, Aegerion announced it has reached preliminary agreements in principle with the Department of Justice and the Securities and Exchange Commission regarding a settlement of ongoing investigations into the Company's sales activities and disclosures related to JUXTAPID® (lomitapide) capsules. Aegerion has agreed to pay $40 million to the Department of Justice and the Securities and Exchange Commission. Aegerion has also agreed to plead guilty to two misdemeanor misbranding violations of the Food, Drug and Cosmetic Act based on 1) alleged marketing of JUXTAPID with inadequate directions for use and 2) alleged failure to comply with a requirement of the JUXTAPID Risk Evaluation and Mitigation Strategies program. To obtain additional information about the investigation, go to:

http://zlk.9nl.com/aegerion-aegr

or contact Eduard Korsinsky, Esq. either via email at ek@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160513005851/en/